IN8bio's γδ T Cell Manufacturing Breakthrough: Consistent Clinical Outcomes and ISCT Recognition in AML Treatment

IN8bio (Nasdaq: INAB) achieved a significant milestone at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting, receiving the prestigious Host Region (U.S. East) Abstract Award for its proprietary gamma-delta T cell manufacturing platform. The recognition underscores the company’s technological leadership in generating reproducible, clinically-grade cellular therapies.

Clinical Efficacy Speaks for Itself

The INB-100 trial data presents compelling evidence of therapeutic potential. All 10 patients in the initial AML cohort maintained relapse-free status for over one year, achieving a median overall survival of 23.3 months as of January 2024. This durability represents a significant advancement for high-risk acute myeloid leukemia patients receiving haplo-matched allogeneic γδ T cells post-hematopoietic stem cell transplant.

What distinguishes these results is the long-term persistence of γδ T cells observed in treated patients—a first-of-its-kind achievement for allogeneic cellular therapy products at the one-year mark.

The Manufacturing Advantage: Process Over Donor Variability

IN8bio’s DeltEx™ Allo platform demonstrates a critical insight: manufacturing methodology, not donor source, determines final product composition. This process-centric approach delivers three key advantages:

TCR Reprogramming Consistency: Clinical batches uniformly shifted from αβ-TCR to γδ-TCR dominance, with enrichment of Vγ9 clones. This conversion occurred independently of donor starting material—evidence that IN8bio’s proprietary process reliably reprograms T cell populations.

Potency Markers Uniformity: Across multiple manufacturing batches, all products expressed high levels of genes associated with enhanced cancer cytotoxicity, immune activation, and tumor-seeking migration capacity.

Scalability Through Automation: IN8bio has automated its manufacturing pipeline, enabling rapid, reproducible production of cryopreserved doses. This technological infrastructure positions the company to efficiently support ongoing clinical trials and potential future commercialization.

Strategic Implications for Cell Therapy Manufacturing

Kate Rochlin, Chief Operating Officer of IN8bio, emphasized the competitive advantage: “Manufacturing control across all developmental stages—from process optimization through clinical production to product characterization—remains paramount for cellular therapy success. Our consistent ability to produce potent cell products with cytotoxic and trafficking signatures represents a key differentiator.”

The ISCT Abstract Award recognition validates IN8bio’s end-to-end manufacturing expertise. Gene expression profiling confirmed highly potent products across multiple batches, addressing a fundamental challenge in allogeneic cell therapy: reproducibility at scale.

Clinical Pipeline Expansion

The INB-100 trial continues enrolling patients at the recommended Phase 2 dose. Beyond AML applications, IN8bio is advancing autologous DeltEx DRI γδ T cells combined with standard-of-care therapy for glioblastoma, while exploring novel γδ T cell engagers for oncology and autoimmune indications.

The convergence of rigorous manufacturing control, consistent clinical outcomes, and third-party academic recognition positions IN8bio as a meaningful player in the evolving gamma-delta T cell immunotherapy landscape.